Publicacions en col·laboració amb investigadors/es de Hospital de la Santa Creu i Sant Pau (7)

2023

  1. Correction to: SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022) (Clinical and Translational Oncology, (2023), 25, 9, (2665-2678), 10.1007/s12094-023-03203-8)

    Clinical and Translational Oncology

  2. SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2665-2678

2019

  1. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

    npj Breast Cancer, Vol. 5, Núm. 1

2018

  1. Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

    Clinical Cancer Research, Vol. 24, Núm. 23, pp. 5820-5829

  2. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification

    Clinical Cancer Research, Vol. 24, Núm. 8, pp. 1845-1852

2017

  1. Efficacy of neoadjuvant carboplatin plus docetaxel in triple-negative breast cancer: Combined analysis of two cohorts

    Clinical Cancer Research, Vol. 23, Núm. 3, pp. 649-657

2012

  1. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

    Cancer, Vol. 118, Núm. 1, pp. 241-247